PIN29 ESTIMATION OF THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A TEST AND TREAT (TT) ANTIRETROVIRAL (ARV) REGIMEN FOR TREATMENT-NAIVE PATIENTS WITH HIV-1 INFECTION IN THE UNITED STATES

May 1, 2019, 00:00
10.1016/j.jval.2019.04.900
https://www.valueinhealthjournal.com/article/S1098-3015(19)31092-7/fulltext
Title : PIN29 ESTIMATION OF THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A TEST AND TREAT (TT) ANTIRETROVIRAL (ARV) REGIMEN FOR TREATMENT-NAIVE PATIENTS WITH HIV-1 INFECTION IN THE UNITED STATES
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)31092-7&doi=10.1016/j.jval.2019.04.900
First page :
Section Title :
Open access? : No
Section Order : 10451
Categories :
Tags :
Regions :
ViH Article Tags :